Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

G20 leaders urged to provide funds for COVID-19 vaccines, drugs, tests

Published 11/19/2020, 01:00 PM
Updated 11/19/2020, 01:55 PM
© Reuters. FILE PHOTO: The word

By Stephanie Nebehay

GENEVA (Reuters) - G20 leaders must help close a funding gap to buy vaccines, drugs and tests to combat the COVID-19 pandemic, a letter from South Africa's president, Norway's prime minister, and the heads of the World Health Organization and European Commission said.

The letter, seen by Reuters, was sent ahead of the Group of 20's virtual summit at the weekend in Riyadh organised by Saudi Arabia, which currently holds the rotating presidency of the club of rich nations and big emerging powers.

"A commitment by G20 leaders at the G20 summit in Riyadh to invest substantially in the ACT (Access to COVID-19 Tools) Accelerator's immediate funding gap of US $4.5 billion will immediately save lives, lay the groundwork for mass procurement and delivery of COVID-19 tools around the world, and provide an exit strategy out of this global economic and human crisis," it said.

The letter also called on G20 leaders to commit jointly to "a proportion of future stimulus" spending on the tools, which are particularly aimed at securing supplies for lower income countries.

The signatories were South African President Cyril Ramaphosa, Norway's Prime Minister Erna Solberg, World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus and Ursula von der Leyen, president of the European Commission.

"Engaging finance ministers now to actually raise all the money that we need, not only the urgent money needed for 2020 but actually make sure that we are fully funding the total work of the ACT Accelerator is so important," Dag Inge Ulstein, Norway's minister of international development, told Reuters in Geneva.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"It's the next weeks that will be very, very crucial," he said.

The facility set up by the WHO and the GAVI vaccine group has exceeded an interim target of raising more than $2 billion to buy and distribute COVID-19 shots for poorer countries, but said last week it still needed more.

Roughly $28 billion is needed to fund fully the procurement and distribution of vaccines, drugs and tests, which von der Leyen said last week was equivalent to “the same sum the transport sector and the global tourism sector lose in just two days of lockdown.”

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.